Yes, us long-term holders got burned by that. The whole business model changed.
Double-edged sword - if they didn't come up with EPP, there would be no approval. But by coming up with EPP, they now have a overpriced drug that no one can afford unless you're subsidized by a govt.
Had I known all this long ago, I would have cashed out at $1 (CUV) for sure.
Still a good investment at these levels if Phase III results are statistically significant.
Market Data 
Markets 
AI
